Navigation Links
Acclarent, Inc. Granted Key Patent Covering Balloon Sinuplasty(TM) Technologies

MENLO PARK, Calif., May 4 /PRNewswire/ -- Acclarent, Inc., the pioneer of Balloon Sinuplasty(TM) technologies for use in the treatment of chronic sinusitis, announced today that the U.S. Patent and Trademark Office awarded U.S. Patent Number 7,500,971, entitled "Devices, Systems and Methods for Treating Disorders of the Ear, Nose and Throat," to the company. This patent and Acclarent's earlier 7,462,175 patent are directed to methods for treating a paranasal sinus ostium, such as the maxillary sinus ostium, either through the nostril or other routes. The patented methods include advancing a balloon through a guide and using the balloon to dilate a paranasal sinus ostium. "In addition to securing protection for this early innovation, we believe this key patent underscores Acclarent's strength in intellectual property and deepens the cornerstone of our patent portfolio for Balloon Sinuplasty(TM)," states Acclarent CEO, Bill Facteau.

With this latest patent, Acclarent now owns or has exclusive rights to nine issued U.S. patents and over 120 pending U.S. and foreign patent applications.

"Acclarent's innovative Balloon Sinuplasty(TM) technology has been used by physicians throughout the world to improve the quality of life for thousands of patients suffering from chronic rhinosinusitis," said Facteau. "Acclarent is committed to continuing its leadership in innovation. This patent protects an important portion of Acclarent's technology assets and further differentiates Acclarent as a leader in the ENT community. The validation by the USPTO of our invention is a significant step in continuing to provide physicians and patients with access to safe and effective minimally invasive technology."


Acclarent is a medical technology company dedicated to the development of innovative products providing new technologies to further meet the needs of ENT patients.

Acclarent's initial focus is on achieving the goals of sinus surgery with novel, endoscopic, catheter-based tools - Balloon Sinuplasty(TM) devices. Through the Balloon Sinuplasty(TM) technology and our Relieva(R) product portfolio we offer ENT patients alternatives to conventional endoscopic surgical approaches. Through our core technologies and commitment to innovation, Acclarent will continue to advance novel devices in all areas of ENT. Acclarent markets and sells its products worldwide and has been used by thousands of physicians globally.

SOURCE Acclarent, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Acclarent, Inc. Closes $26 Million Financing
2. Lilly Granted Preliminary Injunction to Prevent Launch of Generic Raloxifene
3. Hahnemann University Hospital Granted Surgical Fellowship Training Program for Pelvic Floor Disorders
4. Tolera Therapeutics Granted Orphan Drug Designation for Organ Transplant Rejection Drug
5. Rib-X Granted Key Antibiotic Patent in China
6. MonoSol Rx Granted U.S. Article of Manufacture Patent
7. Microfluidic Systems (MFSI) is Granted a Microfluidic Cartridge Patent for DNA Separation
8. Skinvisible Patent Granted for Japan
9. Lilly Granted Temporary Restraining Order to Halt Launch of Generic Raloxifene
10. The 2009 Damon Runyon-Rachleff Innovation Award Granted for Pioneering Ideas for Early Detection of Ovarian and Lung Cancers, Bone Marrow Transplant Safety, and Discovery of New Genetic Markers for Cancer
11. Lupin is Granted USFDA Approval for Levetiracetam Tablets
Post Your Comments:
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell ... pain and the benefits of holistic treatments, Serenity Recovery Center of Marne, ... Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... a startling report released today, National Safety Council research ... proven plan to eliminate prescription opioid overdoses. Prescription Nation ... tackling the worst drug crisis in recorded U.S. history, assigned a ... , New Mexico , Tennessee ... failing states, three – Michigan , ...
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
(Date:6/23/2016)...  Guerbet announced today that it has been named ... . One of 12 suppliers to receive ... support of Premier members through exceptional local customer service ... to lower costs. ... outstanding customer service from Premier," says Massimo Carrara ...
Breaking Medicine Technology: